SRC and breast cancer: Treatment with FK866 also reduced fatty acid synthesis in tumor cells of various origins including Snb-19 glioblastoma cells, Src-transformed 3T3 cells (3T3-Src), and MCF-7 breast cancer cells by 90%, 91%, and 52%, respectively (*p<0.0001, Figure 2B).